S&P 500

5.222,68

0,16%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (ALLO) Notícias

ALLO

Allogene Therapeutics (ALLO)

Allogene Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALLO

1 2 3 4 5 6 7 8 9 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
06/05/2024	09:30	GlobeNewswire Inc.	Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
26/04/2024	09:30	GlobeNewswire Inc.	Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	NASDAQ:ALLO	Allogene Therapeutics Inc
09/04/2024	09:30	GlobeNewswire Inc.	Allogene Therapeutics Announces Q2 Investor Conference Participation	NASDAQ:ALLO	Allogene Therapeutics Inc
14/03/2024	17:05	GlobeNewswire Inc.	Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
12/03/2024	09:30	GlobeNewswire Inc.	Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease	NASDAQ:ALLO	Allogene Therapeutics Inc
05/03/2024	10:30	GlobeNewswire Inc.	Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
28/02/2024	10:30	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	NASDAQ:ALLO	Allogene Therapeutics Inc
16/02/2024	10:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLO	Allogene Therapeutics Inc
16/02/2024	10:30	GlobeNewswire Inc.	Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	NASDAQ:ALLO	Allogene Therapeutics Inc
31/01/2024	19:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALLO	Allogene Therapeutics Inc
22/01/2024	18:11	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ALLO	Allogene Therapeutics Inc
16/01/2024	18:05	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	NASDAQ:ALLO	Allogene Therapeutics Inc
04/01/2024	18:15	GlobeNewswire Inc.	Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	NASDAQ:ALLO	Allogene Therapeutics Inc
04/01/2024	18:05	GlobeNewswire Inc.	Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	NASDAQ:ALLO	Allogene Therapeutics Inc
03/01/2024	18:05	GlobeNewswire Inc.	Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:ALLO	Allogene Therapeutics Inc
09/12/2023	14:00	GlobeNewswire Inc.	Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology	NASDAQ:ALLO	Allogene Therapeutics Inc
01/12/2023	10:30	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in December Investor Conference	NASDAQ:ALLO	Allogene Therapeutics Inc
03/11/2023	13:00	GlobeNewswire Inc.	Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting	NASDAQ:ALLO	Allogene Therapeutics Inc
03/11/2023	13:00	GlobeNewswire Inc.	Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting	NASDAQ:ALLO	Allogene Therapeutics Inc
02/11/2023	17:41	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALLO	Allogene Therapeutics Inc
02/11/2023	17:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALLO	Allogene Therapeutics Inc
02/11/2023	17:02	GlobeNewswire Inc.	Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
02/11/2023	10:00	GlobeNewswire Inc.	Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology	NASDAQ:ALLO	Allogene Therapeutics Inc
30/10/2023	09:30	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in November Investor Conferences	NASDAQ:ALLO	Allogene Therapeutics Inc
26/10/2023	09:30	GlobeNewswire Inc.	Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023	NASDAQ:ALLO	Allogene Therapeutics Inc
17/10/2023	17:34	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ALLO	Allogene Therapeutics Inc
16/10/2023	09:30	GlobeNewswire Inc.	Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer	NASDAQ:ALLO	Allogene Therapeutics Inc
27/09/2023	10:09	GlobeNewswire Inc.	Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting	NASDAQ:ALLO	Allogene Therapeutics Inc
05/09/2023	09:30	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in September Investor Conference	NASDAQ:ALLO	Allogene Therapeutics Inc
14/08/2023	20:28	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ALLO	Allogene Therapeutics Inc